Researchers evaluated BPC-157 and two newly designed hybrid peptide analogs (CIARA-1 and CIARA-2) as competitive inhibitors of acetylcholinesterase, an enzyme target in Alzheimer’s disease management. All three compounds showed reversible competitive inhibition, with the hybrid analogs demonstrating superior potency compared to native BPC-157. While the peptides are significantly less potent than approved AChE inhibitors, the study validates BPC-157 as a viable scaffold for developing multifunctional neurodegenerative therapeutics through rational structural modification.
For your business
BPC-157 shows reversible AChE inhibition in vitro; hybrid analogs suggest structural optimization may enhance potency for neurodegenerative applications.